Highlights From the 2021 European Hematology Association Congress on Multiple Myeloma

Video

Nina Shah, MD, highlights some of the major takeaways in multiple myeloma from the 2021 European Hematology Association Congress.

Nina Shah, MD: One of the major highlights from the European Hematology Association Congress from 2021, particularly for multiple myeloma, was the presentation of the overall survival data from the MAIA trial [NCT02252172]. In this trial, patients with newly diagnosed multiple myeloma who were transplant-ineligible were randomized to receive daratumumab (Darzalex), lenalidomide (Revlimid), and dexamethasone versus lenalidomide and dexamethasone with a primary end point of PFS [progression-free survival]. We already knew that the patients did better from a PFS standpoint [if they] got the triplet therapy. Finally, we now have overall survival data, and that data look nice for these patients who are transplant ineligible and who may be getting daratumumab, lenalidomide, and dexamethasone. They had a significant overall survival improvement versus lenalidomide and dexamethasone. That was one of the biggest takeaways from that Congress because it makes you feel better about choosing that regimen and has changed the way that a lot of us approach transplant-ineligible multiple myeloma.

Recent Videos
Combining daratumumab with other agents is one strategy that investigators are exploring in the smoldering multiple myeloma field.
A substantial portion of patients who received daratumumab in the AQUILA study were able to delay disease progression to active multiple myeloma.
The approval of daratumumab validates the notion of using limited therapy to help delay progression from smoldering disease to multiple myeloma.
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
Andrezj Jakubowiak, MD, PhD, prioritizes KRd-based regimens for the treatment of high-risk newly diagnosed disease in the post-transplant setting.
Although a similar proportion achieved MRD negativity at the 10 to the –6 power, not enough studies have analyzed MRD at this level for multiple myeloma.
Related Content
From phase 3 trial updates to results on trispecific antibodies, ASH 2025 may feature a variety of practice-shifting presentations across multiple myeloma.

ASH 2025: Which Presentations Will Move the Multiple Myeloma Needle?

Russ Conroy
December 4th 2025
Article

From phase 3 trial updates to results on trispecific antibodies, ASH 2025 may feature a variety of practice-shifting presentations across multiple myeloma.

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Evolutions Across NSCLC, Multiple Myeloma, and AML at Georgia Cancer Center

Girindra Raval, MD;Amany Keruakous, MD;Daniel Peters, MD
December 1st 2025
Podcast

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Two belantamab mafodotin regimens have been approved in multiple myeloma despite the FDA’s ODAC committee voting against the proposed dosages due to ocular toxicities.

FDA Approves Belantamab Mafodotin in R/R Multiple Myeloma

Tim Cortese
October 23rd 2025
Article

Belantamab mafodotin has been approved for multiple myeloma, despite the FDA’s ODAC voting against the treatment due to ocular toxicities.

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025
Podcast

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

The safety profile of venetoclax combined with bortezomib and dexamethasone was consistent with previously published results.

Venetoclax Combo Achieves Mixed Results in Relapsed/Refractory Multiple Myeloma

Tim Cortese
October 17th 2025
Article

Venetoclax with bortezomib and dexamethasone led to a median PFS of 23.4 months compared with 11.4 months with placebo in patients with R/R MM.

Investigators plan to present detailed findings from the MajesTEC-3 study at a future medical conference and share them with regulatory authorities.

Teclistamab/SC Daratumumab Improves Survival in R/R Multiple Myeloma

Russ Conroy
October 16th 2025
Article

Investigators plan to present detailed findings from the MajesTEC-3 study at a future medical conference and share them with regulatory authorities.